USANA Health Sciences (NYSE: USNA) reported Q2 EPS of ($0.07), $0.50 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $223 million versus the consensus estimate of $235 million.

GUIDANCE:

USANA Health Sciences sees FY2026 EPS of $0.76, versus the consensus of $2.12. USANA Health Sciences sees FY2026 revenue of $750 million, versus the consensus of $945.1 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.